



Clinical trial results:

B-Fine: An open label, single arm study to mechanistically interrogate the therapeutic effect of GSK3228836 in patients with Chronic Hepatitis B via intrahepatic immunophenotyping

Summary

EudraCT number	2020-002000-39
Trial protocol	NL GB
Global end of trial date	30 November 2023

Results information

Result version number	v1 (current)
This version publication date	15 December 2024
First version publication date	15 December 2024

Trial information

Trial identification

Sponsor protocol code	212602
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04544956
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS
Public contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 January 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	30 November 2023
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To assess the effect of 12 weeks of GSK3228836 on serum hepatitis B virus surface antigen (HBsAg) levels in participants with chronic hepatitis B (CHB)

Protection of trial subjects:

Not applicable

Background therapy:

Protocol inclusion criterion 2 states: Participants who have documented chronic HBV infection ≥ 6 months prior to screening AND currently receiving stable nucleos(t)ide analogue therapy, defined as no changes to their nucleos(t)ide regimen from at least 6 months prior to screening and with no planned changes to the stable regimen over the duration of the study.

Evidence for comparator: -

Actual start date of recruitment	06 October 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 4
Country: Number of subjects enrolled	Netherlands: 2
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	United States: 3
Worldwide total number of subjects	12
EEA total number of subjects	2

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	12
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This was an open label, single arm study to mechanistically interrogate the therapeutic effect of GSK3228836 in participants with Chronic Hepatitis B via intrahepatic immunophenotyping.

Pre-assignment

Screening details:

A total of 12 participants were enrolled in this study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	GSK3228836 300 mg
-----------	-------------------

Arm description:

Participants on stable nucleos(t)ide therapy received GSK3228836 300 milligrams (mg) subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).

Arm type	Experimental
Investigational medicinal product name	GSK3228836
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered two subcutaneous injections for 300 milligrams dose.

Number of subjects in period 1	GSK3228836 300 mg
Started	12
Completed	11
Not completed	1
Consent withdrawn by subject	1

Baseline characteristics

Reporting groups

Reporting group title	GSK3228836 300 mg
-----------------------	-------------------

Reporting group description:

Participants on stable nucleos(t)ide therapy received GSK3228836 300 milligrams (mg) subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).

Reporting group values	GSK3228836 300 mg	Total	
Number of subjects	12	12	
Age categorical			
Units: Participants			
Adults (18-64 years)	12	12	
Age continuous			
Units: years			
arithmetic mean	48.8		
standard deviation	± 8.48	-	
Sex: Female, Male			
Gender categories (with 0<n<11) are combined into one 'De-identified' category to maintain participant confidentiality and privacy, as they could lead to participant re-identification.			
Units: Participants			
De-identified	12	12	
Race/Ethnicity, Customized			
Race categories (with 0<n<11) are combined into one 'De-identified' category to maintain participant confidentiality and privacy, as they could lead to participant re-identification.			
Units: Subjects			
De-identified	12	12	

End points

End points reporting groups

Reporting group title	GSK3228836 300 mg
Reporting group description: Participants on stable nucleos(t)ide therapy received GSK3228836 300 milligrams (mg) subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).	

Primary: Percentage of participants achieving serum hepatitis B virus surface antigen (HBsAg) level less than (<) lower limit of quantitation (LLOQ)

End point title	Percentage of participants achieving serum hepatitis B virus surface antigen (HBsAg) level less than (<) lower limit of quantitation (LLOQ) ^[1]
End point description: Percentage of participants achieving serum HBsAg level <LLOQ were reported. Percentage values are rounded-off. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment.	
End point type	Primary
End point timeframe: Up to Week 12	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: There are no statistical data to report.	

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[2]			
Units: Percentage of participants	25			

Notes:

[2] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with Sustained HBsAg Response (HBsAg <LLOQ) for 24 weeks after the planned and actual end of GSK3228836 treatment

End point title	Percentage of participants with Sustained HBsAg Response (HBsAg <LLOQ) for 24 weeks after the planned and actual end of GSK3228836 treatment
End point description: Sustained HBsAg response is defined as HBsAg <LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment.	
End point type	Secondary
End point timeframe: Up to 24 weeks off treatment (Study Weeks 12 to 36)	

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[3]			
Units: Percentage of participants				
24 Weeks after Planned End of GSK3228836 Treatment	8			
24 Weeks after Actual End of GSK3228836 Treatment	8			

Notes:

[3] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving Sustained Virologic Response (HBsAg < LLOQ and HBV DNA < LLOQ) for 24 weeks after the planned and actual end of GSK3228836 treatment

End point title	Percentage of participants achieving Sustained Virologic Response (HBsAg < LLOQ and HBV DNA < LLOQ) for 24 weeks after the planned and actual end of GSK3228836 treatment
-----------------	---

End point description:

Sustained virologic response is defined as HBsAg <LLOQ and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) <LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 24 weeks off treatment (Study Weeks 12 to 36)

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[4]			
Units: Percentage of participants				
24 Weeks after Planned End of GSK3228836 Treatment	8			
24 Weeks after Actual End of GSK3228836 Treatment	8			

Notes:

[4] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving HBsAg <LLOQ at indicated time

points

End point title	Percentage of participants achieving HBsAg <LLOQ at indicated time points
-----------------	---

End point description:

Percentage of participants achieving HBsAg <LLOQ were assessed at indicated time points. Percentage values are rounded-off. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week -1), treatment Day 78 and off treatment (OT) Day 162

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[5]			
Units: Percentage of participants				
Baseline (Week -1), n=12	0			
Treatment Day 78, n=10	30			
Off Treatment Day 162, n=11	18			

Notes:

[5] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving HBV DNA <LLOQ at indicated time points

End point title	Percentage of participants achieving HBV DNA <LLOQ at indicated time points
-----------------	---

End point description:

Percentage of participants achieving HBV DNA <LLOQ were assessed at indicated time points. Percentage values are rounded-off. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week -1), treatment Day 78 and off treatment Day 162

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[6]			
Units: Percentage of participants				
Baseline (Week -1), n=12	92			
Treatment Day 78, n=9	78			
Off Treatment Day 162, n=11	100			

Notes:

[6] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving HBsAg <LLOQ and HBV DNA <LLOQ at indicated time points

End point title	Percentage of participants achieving HBsAg <LLOQ and HBV DNA <LLOQ at indicated time points
-----------------	---

End point description:

Percentage of participants achieving HBsAg <LLOQ and HBV DNA <LLOQ were assessed at indicated time points. Percentage values are rounded-off. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week -1), treatment Day 78 and off treatment Day 162

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[7]			
Units: Percentage of participants				
Baseline (Week -1), n=12	0			
Treatment Day 78, n=10	20			
Off Treatment Day 162, n=11	18			

Notes:

[7] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with categorical change from Baseline in HBsAg Values at indicated time points

End point title	Percentage of participants with categorical change from Baseline in HBsAg Values at indicated time points
-----------------	---

End point description:

Participants who achieved a decline in HBsAg values from Baseline were reported. Participants were

categorized in the following categorical HBsAg decline of <0.5, greater than or equal to (\geq) 0.5, ≥ 1 , ≥ 1.5 , and ≥ 3 log₁₀ international units per milliliter (IU/mL). The 'HBsAg < LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from Baseline values. Percentage values are rounded-off. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
End point timeframe:	
Baseline (Week -1), Treatment Week 12 and off treatment Week 24	

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	11 ^[8]			
Units: Percentage of participants				
Treatment (Treat.) Week 12, HBsAg < LLOQ, n=10	30			
Treat. Week12, HBsAg decline <0.5 log ₁₀ IU/mL,n=10	10			
Treat.Week 12,HBsAg decline ≥ 0.5 log ₁₀ IU/mL,n=10	90			
Treat. Week 12,HBsAg decline ≥ 1 log ₁₀ IU/mL, n=10	80			
Treat.Week12,HBsAg decline ≥ 1.5 log ₁₀ IU/mL, n=10	80			
Treat. Week12,HBsAg decline ≥ 3 log ₁₀ IU/mL, n=10	50			
Off Treatment (OT) Week 24, HBsAg < LLOQ, n=11	18			
OT Week 24, HBsAg decline <0.5 log ₁₀ IU/mL, n=11	73			
OT Week 24, HBsAg decline ≥ 0.5 log ₁₀ IU/mL, n=11	27			
OT Week 24, HBsAg decline ≥ 1 log ₁₀ IU/mL, n=11	27			
OT Week 24, HBsAg decline ≥ 1.5 log ₁₀ IU/mL, n=11	27			
OT Week 24, HBsAg decline ≥ 3 log ₁₀ IU/mL, n=11	18			

Notes:

[8] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with alanine aminotransferase (ALT) greater than (>)3 times upper limit of normal (ULN) at indicated time points

End point title	Number of participants with alanine aminotransferase (ALT) greater than (>)3 times upper limit of normal (ULN) at indicated time points
-----------------	---

End point description:

Blood samples were collected at indicated time points to assess ALT levels. The ALT normalization (ALT \leq upper limit of normal [ULN]) over time in absence of rescue medication in participants with Baseline

ALT>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. The "n" represents the number of participants with Baseline ALT > ULN and ALT data at that visit. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week -1), treatment Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; off treatment Days 1, 8, 22, 50, 78, 106, 134 and 162

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[9]			
Units: Participants				
Baseline (Week -1), n=12	0			
Treatment Day 8, n=12	0			
Treatment Day 15, n=11	0			
Treatment Day 22, n=12	0			
Treatment Day 29, n=11	0			
Treatment Day 36, n=11	1			
Treatment Day 43, n=10	1			
Treatment Day 50, n=10	1			
Treatment Day 57, n=10	1			
Treatment Day 64, n=11	1			
Treatment Day 71, n=11	1			
Treatment Day 78, n=11	0			
Off Treatment Day 1, n=10	0			
Off Treatment Day 8, n=11	0			
Off Treatment Day 22, n=11	0			
Off Treatment Day 50, n=11	0			
Off Treatment Day 78, n=9	0			
Off Treatment Day 106, n=11	1			
Off Treatment Day 134, n=9	0			
Off Treatment Day 162, n=11	0			

Notes:

[9] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With HBe Antibody (Anti-HBeAg) Levels

End point title	Number of Participants With HBe Antibody (Anti-HBeAg) Levels
-----------------	--

End point description:

Blood samples were collected to assess HBe antibody levels and results reported are for Baseline HBeAg positive participants. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
End point timeframe:	
Baseline (Week -1), treatment Days 29, 36, and 57; off treatment Days 1, 8, 22, 50, 78, 106, 134 and 162	

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[10]			
Units: Participants				
Baseline (Week -1), n=12	11			
Treatment Day 29, n=11	11			
Treatment Day 36, n=1	0			
Treatment Day 57, n=10	9			
Off Treatment Day 1, n=10	9			
Off Treatment Day 8, n=11	10			
Off Treatment Day 22, n=11	10			
Off Treatment Day 50, n=11	10			
Off Treatment Day 78, n=11	10			
Off Treatment Day 106, n=11	10			
Off Treatment Day 134, n=9	8			
Off Treatment Day 162, n=11	10			

Notes:

[10] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of HBsAg at indicated time points

End point title	Actual values of HBsAg at indicated time points
End point description:	
Blood samples were collected from participants at indicated time points to assess HBsAg levels. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).	
End point type	Secondary
End point timeframe:	
Baseline (Week -1), treatment Day 78 and off treatment Day 162	

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[11]			
Units: Log10 IU/mL				
arithmetic mean (standard deviation)				
Baseline (Week -1), n=12	3.29 (± 0.590)			

Treatment Day 78, n=10	0.33 (\pm 1.432)			
Off Treatment Day 162, n=11	2.08 (\pm 1.933)			

Notes:

[11] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in HBsAg at indicated time points

End point title	Mean change from Baseline in HBsAg at indicated time points
-----------------	---

End point description:

Blood samples were collected from participants at indicated time points to assess HBsAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles). Participants who had Baseline and at least 1 post-Baseline visit values were included in analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week -1), treatment Day 78 and off treatment Day 162

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	11 ^[12]			
Units: Log10 IU/mL				
arithmetic mean (standard deviation)				
Treatment Day 78, n=10	-2.923 (\pm 1.5803)			
Off Treatment Day 162, n=11	-1.183 (\pm 1.8343)			

Notes:

[12] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of HBV DNA at indicated time points

End point title	Actual values of HBV DNA at indicated time points
-----------------	---

End point description:

Blood samples were collected from participants at indicated time points to assess HBV DNA levels. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week -1), treatment Day 78 and off treatment Day 162

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[13]			
Units: Log10 IU/mL				
arithmetic mean (standard deviation)				
Baseline (Week -1), n=12	0.43 (± 0.849)			
Treatment Day 78, n=9	0.31 (± 0.611)			
Off Treatment Day 162, n=11	0.24 (± 0.525)			

Notes:

[13] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from Baseline in HBV DNA at indicated time points

End point title	Mean change from Baseline in HBV DNA at indicated time points
-----------------	---

End point description:

Blood samples were collected from participants at indicated time points to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles). Participants who had Baseline and at least 1 post-Baseline visit values were included in analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week -1), treatment Day 78 and off treatment Day 162

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	11 ^[14]			
Units: Log10 IU/mL				
arithmetic mean (standard deviation)				
Treatment Day 78, n=9	-0.271 (± 1.1145)			
Off Treatment Day 162, n=11	-0.237 (± 0.7871)			

Notes:

[14] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Actual values of HB surface antibody (anti-HBsAg) levels at indicated time points

End point title	Actual values of HB surface antibody (anti-HBsAg) levels at indicated time points
-----------------	---

End point description:

Blood samples were collected from participants at indicated time points to assess anti-HBsAg levels. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week -1) and off treatment Days 1 and 162

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[15]			
Units: Log10 IU/mL				
arithmetic mean (standard deviation)				
Baseline (Week -1), n=12	0.60 (± 0.000)			
Off Treatment Day 1, n=10	0.71 (± 0.238)			
Off Treatment Day 162, n=11	0.70 (± 0.260)			

Notes:

[15] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the concentration-time curve (AUC) for ALT at indicated time points

End point title	Area under the concentration-time curve (AUC) for ALT at indicated time points
-----------------	--

End point description:

Blood samples were collected from participants to assess AUC for ALT. On-treatment blood samples were collected from Weeks 1 to 12 and follow-up blood samples were collected from Weeks 12 to 36. AUC was calculated and presented for on-treatment (12 Weeks), follow-up (24 weeks), and On-treatment + follow-up (Weeks 1 to 36). Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the 'Overall Number of Participants Analyzed' field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Study Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 20, 24, 28, 32 and 36

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[16]			
Units: Weeks*International Units Per Liter				
arithmetic mean (standard deviation)				
On-Treatment (12 Weeks), n=12	494.75 (± 562.593)			
Follow-up (24 weeks), n=11	650.58 (± 462.762)			
On-Treatment + Follow-Up (Weeks 1 to 36), n=11	1173.72 (± 836.768)			

Notes:

[16] - ITT Set

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Maximum ALT

End point title	Time to Maximum ALT
End point description:	
Time to maximum ALT (maximum peak in ALT) during 36 week (treatment + follow-up) is defined as time from Baseline to the time of first peak in ALT. Intent to Treat (ITT) Set that included all participants who received at least one dose of study treatment. 99999 indicates median and 95% CI (upper limit) could not be derived, as <50% of participants experienced the event within the treatment arm.	
End point type	Secondary
End point timeframe:	
Up to Study Week 36	

End point values	GSK3228836 300 mg			
Subject group type	Reporting group			
Number of subjects analysed	12 ^[17]			
Units: Weeks				
median (confidence interval 95%)	99999 (27.1 to 99999)			

Notes:

[17] - ITT Set

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to Week 36

Adverse event reporting additional description:

All-cause mortality, serious adverse events and non-serious adverse events were reported for the Safety Population which consisted of all participants who received at least one dose of study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

Reporting groups

Reporting group title	GSK3228836 300 mg
-----------------------	-------------------

Reporting group description:

Participants on stable nucleos(t)ide therapy received GSK3228836 300 milligrams (mg) subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).

Serious adverse events	GSK3228836 300 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 12 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	GSK3228836 300 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 12 (91.67%)		
General disorders and administration site conditions			
Pyrexia			
alternative dictionary used: 26.1			
26.1			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Injection site pain			
alternative dictionary used: 26.1			
26.1			

subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	40		
Injection site bruising			
alternative dictionary used: 26.1 26.1			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	10		
Fatigue			
alternative dictionary used: 26.1 26.1			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Injection site pruritus			
alternative dictionary used: 26.1 26.1			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	18		
Injection site erythema			
alternative dictionary used: 26.1 26.1			
subjects affected / exposed	7 / 12 (58.33%)		
occurrences (all)	30		
Chest discomfort			
alternative dictionary used: 26.1 26.1			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Injection site discomfort			
alternative dictionary used: 26.1 26.1			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Injection site swelling			
alternative dictionary used: 26.1 26.1			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Immune system disorders			
Seasonal allergy			
alternative dictionary used: 26.1 26.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Reproductive system and breast disorders</p> <p>Prostatomegaly</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Investigations</p> <p>SARS-CoV-2 test positive</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Platelet count decreased</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Creatinine renal clearance decreased</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Alanine aminotransferase increased</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p> <p>1 / 12 (8.33%)</p> <p>1</p> <p>1 / 12 (8.33%)</p> <p>1</p> <p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Injury, poisoning and procedural complications</p> <p>Procedural pain</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Contusion</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Post procedural discomfort</p> <p>alternative dictionary used: 26.1</p>	<p>3 / 12 (25.00%)</p> <p>3</p> <p>1 / 12 (8.33%)</p> <p>1</p>		

26.1			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Nervous system disorders			
Sensory disturbance			
alternative dictionary used: 26.1			
26.1			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Headache			
alternative dictionary used: 26.1			
26.1			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Dizziness			
alternative dictionary used: 26.1			
26.1			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Eye disorders			
Diplopia			
alternative dictionary used: 26.1			
26.1			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Gastrointestinal disorders			
Diarrhoea			
alternative dictionary used: 26.1			
26.1			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Abdominal discomfort			
alternative dictionary used: 26.1			
26.1			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Nausea			
alternative dictionary used: 26.1			
26.1			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Dyspepsia			
alternative dictionary used: 26.1			

26.1 subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Hepatobiliary disorders Hypertransaminasaemia alternative dictionary used: 26.1 26.1 subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Skin and subcutaneous tissue disorders Pruritus alternative dictionary used: 26.1 26.1 subjects affected / exposed occurrences (all) Hyperhidrosis alternative dictionary used: 26.1 26.1 subjects affected / exposed occurrences (all) Acne alternative dictionary used: 26.1 26.1 subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 2 1 / 12 (8.33%) 1 1 / 12 (8.33%) 1		
Renal and urinary disorders Dysuria alternative dictionary used: 26.1 26.1 subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Musculoskeletal and connective tissue disorders Muscle tightness alternative dictionary used: 26.1 26.1 subjects affected / exposed occurrences (all) Back pain alternative dictionary used: 26.1 26.1 subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1 1 / 12 (8.33%) 1		

<p>Arthralgia</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>2</p>		
<p>Pain in extremity</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Neck pain</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Myalgia</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Muscle twitching</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Infections and infestations</p> <p>Rhinitis</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>COVID-19</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Respiratory tract infection viral</p> <p>alternative dictionary used: 26.1 26.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p> <p>1 / 12 (8.33%)</p> <p>1</p> <p>1 / 12 (8.33%)</p> <p>1</p>		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 March 2021	Protocol amendment 1: The primary driver for this protocol amendment was to reduce the number of sampling timepoints for peripheral blood mononuclear cells (PBMC) analysis, due to the increased blood volume required for this analysis. Other key changes include: a description of the risk of Coronavirus disease-2019 (Covid-19) infection in the hepatitis B population, added at the request of the Medicines & Healthcare products Regulatory Agency (MHRA); an update to the time to maximum alanine aminotransferase (ALT) analysis method; additional guidance and clarity for Investigators has been added; corrections to visit windows and visit numbering in the schedule of activities (SoA).

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported